Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma

This study has been terminated.
(Inadequate patient accrual)
Sponsor:
Information provided by:
Penn State University
ClinicalTrials.gov Identifier:
NCT00934518
First received: July 7, 2009
Last updated: July 28, 2010
Last verified: July 2009

July 7, 2009
July 28, 2010
July 2009
July 2016   (final data collection date for primary outcome measure)
To estimate the incidence rate of acute and late toxicities associated with combined cetuximab and image guided intensity modulated reirradiation in patients with recurrent squamous cell cancer of the head and neck. [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00934518 on ClinicalTrials.gov Archive Site
  • To estimate the median and one-year, disease-free, and overall survival rates of the treated patients. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • To determine the pattern of disease progression in treated patients. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • To identify the impact of cetuximab and image guided intensity modulated reirradiation on patients' quality of life. [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
Image Guided Intensity Modulated Reirradiation With Concurrent Cetuximab in the Treatment of Locoregionally Confined Relapsed Squamous Cell Carcinoma of the Head and Neck

The standard treatment for head and neck cancer relapses in previously irradiated patients is controversial. Reirradiation has had some success, but many patients still die from their disease. Cetuximab is helpful in relapsed head and neck cancer, and it improves the effectiveness of radiation in some head and neck cancer patients. But, it has not been studied with reirradiation. The purpose of this study is to see the effects, both good and bad, of reirradiation with cetuximab.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Squamous Cell Cancer of the Head and Neck
  • Radiation: Radiation
    Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
  • Drug: Cetuximab

    Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week

    Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation

Experimental: Radiation and Cetuximab

Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week

Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation

Interventions:
  • Radiation: Radiation
  • Drug: Cetuximab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
30
Not Provided
July 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must have a pathologically confirmed recurrence (reappearance of previously cleared) squamous cell cancer in the upper aerodigestive tract or a second squamous cell primary. Patients may have experienced more than one recurrence as long as the first recurrence occurred ≥6 months following the end of the prior RT.
  • The recurrence or second primary must be confined to the head and neck above the clavicles (loco-regional recurrence).
  • The majority (≥75%) of the tumor volume must have been in areas previously irradiated to ≥45 Gy. The previous irradiation must not exceed a maximum of 75 Gy.
  • Patients must be at least 6 months from prior radiation therapy.
  • If a resection is performed after the diagnosis of recurrence and before enrollment, either microscopic or macroscopic disease must be present (i.e. positive margins or gross residual).
  • Karnofsky Performance Status 60-100.
  • Granulocytes ≥ 1500/mm3, platelets ≥ 100,000/mm3, bilirubin ≤ 1.5 mg/dl, creatinine ≤ 1.5 mg/dl, within 6 weeks prior to registration.
  • Must be able to submit previous radiation records (simulation and portal film if available) in order to assure that cord tolerance is not exceeded.
  • Patients must sign a study-specific informed consent form prior to study entry.
  • The patient must be between the ages of 18 and 75.

Exclusion Criteria:

  • Distant metastases.
  • Completely resected recurrence with negative margins.
  • Other concurrent invasive malignancies.
  • Prior invasive malignancy unless disease free for at least two years (prior in situ malignancies are permissible).
  • Intercurrent medical illnesses which would impair patient tolerance to therapy or limit survival.
  • Pregnant and nursing women are excluded because of the potential teratogenic effects and potential unknown effects on nursing newborns.
  • Previous treatment with cetuximab.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00934518
PSHCI 08-066
Yes
Heath Mackley, M.D., Principal Investigator, Penn State Hershey Cancer Institute
Penn State University
Not Provided
Principal Investigator: Heath B Mackley, MD Penn State Hershey Cancer Institute
Penn State University
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP